Regen Biopharma enters $130K convertible note financing with CFI Capital

Regen BioPharma Inc

Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.
Note matures July 28, 2026; interest payable in common stock at holder's option.
Conversion price set at 60% of lowest trading price over prior 20 trading days on OTC Markets.
Company reserved 15,700,485 common shares for conversion; holder must maintain 5x coverage reserve.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.